TY - JOUR AU - Alhomrani, Dr. Majid PY - 2022/06/15 Y2 - 2024/03/29 TI - Regenerative Medicine Therapies for Osteoarthritis and Cartilage JF - Asian Journal of Pharmaceutics (AJP) JA - AJP VL - 16 IS - 2 SE - REVIEW ARTICLES DO - 10.22377/ajp.v16i2.4382 UR - http://www.asiapharmaceutics.info/index.php/ajp/article/view/4382 SP - AB - <p>Osteoarthritis (OA) has a high burden and impact on society as it affects the quality of life of both young and older<br>patients. OA is a degenerative joint disease characterized by the degeneration of articular cartilage. This cartilage<br>is an avascular, unique matrix composed of chondrocyte cells, which can resist compression and redistribute loads<br>but have poor self-regenerative capacity. Numerous types of treatment are available, such as non-pharmacology<br>treatments involving diet, physiotherapy, exercise, and pharmacological which include different types of drugs.<br>None of these two types has proven to be the ideal treatment, only symptomatic treatment. Total knee replacement<br>is the final and only treatment available and used only when the other types of treatment fails. The intra-articular<br>injection is an alternative treatment for OA, due to the localized nature of the disease. Various types of blood<br>products are currently used, including platelet-rich plasma and orthokine to alert the inflammation response and<br>enhance the healing process. Recently, regenerative treatments have widely been introduced to overcome the<br>limitations of current treatments. Mesenchymal Stromal Cells (MSCs), which can differentiate into chondrocytes,<br>are used to regenerate articular cartilage. In addition, the improvements in tissue engineering technology such as<br>the use of different types of the scaffold as well as blood product and growth factors with MSC have had a great<br>impact in treating OA and regenerating cartilage. This review will discuss the pathogenesis of OA and describes<br>the current clinical management to treat the OA.</p> ER -